Drug profile

The FDA adverse-event record for Clostridium Novyi, 8296;Clostridium Perfringens Type C, Pc8

158 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Clostridium Novyi, 8296;Clostridium Perfringens Type C, Pc8. See the species affected, top reactions, and outcomes below.

158
adverse-event reports
78.5%
death-coded share
Cattle
most-reported species
100
Death - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
158
Total Reports
124
Deaths Reported
78.5%
Death Rate

Active Ingredients

Clostridium Novyi, 8296;Clostridium Perfringens Type C, Pc8

Administration Routes

SubcutaneousUnknownIntramuscular

Species Affected

Cattle 158

Most Affected Breeds

Mixed (Cattle) 108
Aberdeen Angus 19
Holstein-Friesian also known as Holstein 8
Cattle (other) 6
Brangus 4
Red Angus 3
Jersey 3
Simmental 2
Crossbred Bovine/Cattle 2
Texas Longhorn 1

Most Reported Reactions

Death 100
Lack of efficacy - NOS 50
Anaphylactic-type reaction 19
Anaphylaxis 16
Anaphylactoid reaction 10
Unexplained death 8
Lack of efficacy (bacteria) - NOS 8
Injection site swelling 7
Sudden death 7
Injection site abscess 7
Found dead 6
Death by euthanasia 6

Outcome Breakdown

Died
121 (55.3%)
Outcome Unknown
61 (27.9%)
Recovered/Normal
19 (8.7%)
Ongoing
10 (4.6%)
Euthanized
5 (2.3%)
Recovered with Sequela
3 (1.4%)

Clostridium Novyi, 8296;Clostridium Perfringens Type C, Pc8 Adverse Event Insights

158 reports name Clostridium Novyi, 8296;Clostridium Perfringens Type C, Pc8; 124 recorded a death outcome (78.5% of reported events, not a population-level mortality rate). Active ingredient: Clostridium Novyi, 8296;Clostridium Perfringens Type C, Pc8. Administration routes: Subcutaneous, Unknown, Intramuscular.

By species: Cattle (158 reports). By breed: Mixed (Cattle) (108), Aberdeen Angus (19), Holstein-Friesian also known as Holstein (8).

Leading clinical signs: Death (100), Lack of efficacy - NOS (50), Anaphylactic-type reaction (19), Anaphylaxis (16). Outcome, 219 coded reports: Died leads at 55.3%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.